About this entry

Essenlix Corporation is a startup company (Princeton, New Jersey, USA), that uses multidisciplinary approaches to develop a new innovative platform of simple, fast, ultrasensitive, bio/chemical sensing and imaging for life science, diagnostics, and personal health.

We have developed a point of care test called Septiflo that can detect and stratify the Gram status of bacterial infections in a drop of human plasma in under 10 minutes. Results are visualized by the naked eye and semi-quantified using a color score chart. This information can be of immense value in rapid decision-making for the selection of bacterial Gram specific narrow spectrum antibiotics, thus reducing drug resistance and improving outcome. The test is comparable in performance to commercial ELISAs and eubacterial PCR and at the same time surpasses them in simplicity, affordability and adoptability for use in ICUs.

If you would like to be introduced to this team for collaboration, get in touch with the Longitude prize.